

31st October 2014

ASX ANNOUNCEMENT

SUCCESSFUL COMPLETION OF ENTITLEMENT OFFER

Analytica Limited (the **Company**) is pleased to announce that its 1 for 8, \$3.17m Entitlement Offer at 3.0 cents per share, has been very well supported by shareholders, with shareholders applying for 85,540,964 shares raising approximately \$2.56M.

Shares will be allotted on Wednesday 5th November 2014.

Analytica is already employing these funds in domestic marketing activities, in particular the development of links within the clinical community. PeriCoach is the only system that allows clinicians to manage, monitor and motivate their patients between consultations and Analytica is developing training materials to ensure clinicians are receiving the full benefits of the system.

Directors would like to thank the shareholders who participated in the Entitlement Offer and welcome new shareholders.

Bryan Dulhunty
Company Secretary



About Analytica Limited

Analytica's lead product is the PeriCoach™ System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach™ comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.

PeriCoach™ has been approved in Australia with product launches expected in 2014 in Australia, and Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence. The product is not available for sale in the USA.

Analytica is also commercialising the AutoStart™ Infusion System. This is a burette with improved safety and cost reduction features. It is targeting a \$3 billion pa global market, has FDA approval and potential near term cash flow with distribution agreements.